56.33

6.75% 3.56

Hims Hers Health Inc (HIMS)

Overview News Price History Option Chain Financials Why HIMS Down? Discussions Forecast

Hims Hers Health Inc stock is traded at $56.33, with a volume of 41.47M. It is up +6.75% in the last 24 hours and up +13.87% over the past month. Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Previous Close:

$52.77

Open:

$53.18

24h Volume:

41.47M

Relative Volume:

1.13

Market Cap:

$12.66B

Revenue:

$1.78B

Net Income/Loss:

$164.40M

P/E Ratio:

81.64

EPS:

0.69

Net Cash Flow:

$236.51M

1W Performance:

-0.41%

1M Performance:

+13.87%

6M Performance:

+64.56%

1Y Performance:

+161.15%

1-Day Range:

$52.75

$57.51

1-Week Range:

$51.85

$67.37

52-Week Range:

$13.47

$72.98

Hims Hers Health Inc Stock (HIMS) Company Profile

Name

Hims Hers Health Inc

Sector

Consumer Defensive (248)

Industry

Household & Personal Products (33)

Phone

415-851-0195

Address

2269 CHESTNUT ST, SAN FRANCISCO

Employee

1,637

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

HIMS's Discussions on Twitter

Compare HIMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HIMS Hims Hers Health Inc	56.33	12.66B	1.78B	164.40M	236.51M	0.69
PG Procter Gamble Co	164.02	398.31B	83.93B	15.50B	15.03B	6.30
UL Unilever Plc Adr	63.02	156.58B	65.10B	6.16B	0	2.4569
CL Colgate Palmolive Co	90.24	75.32B	19.95B	2.90B	3.47B	3.54
KMB Kimberly Clark Corp	133.55	47.70B	19.75B	2.47B	2.39B	7.34
KVUE Kenvue Inc	21.73	45.83B	15.30B	1.06B	1.45B	0.55

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Reiterated	Needham	Buy
Apr-29-25	Downgrade	TD Cowen	Buy → Hold
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-10-25	Downgrade	Citigroup	Neutral → Sell
Jan-07-25	Initiated	BTIG Research	Buy
Dec-17-24	Initiated	Morgan Stanley	Overweight
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral
Apr-16-24	Downgrade	Jefferies	Buy → Hold
Apr-10-24	Initiated	Canaccord Genuity	Buy
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform
Feb-26-24	Initiated	Leerink Partners	Market Perform
Dec-07-23	Initiated	Imperial Capital	In-line
Jul-28-23	Initiated	TD Cowen	Outperform
Apr-11-23	Initiated	Robert W. Baird	Neutral
Feb-09-23	Upgrade	Jefferies	Hold → Buy
Nov-08-22	Upgrade	BofA Securities	Neutral → Buy
Nov-08-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Oct-17-22	Downgrade	Piper Sandler	Overweight → Neutral
Sep-07-22	Initiated	Truist	Hold
Jul-15-22	Initiated	SVB Leerink	Underperform
Apr-14-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Outperform
Mar-10-22	Initiated	Deutsche Bank	Hold
Dec-02-21	Initiated	Jefferies	Hold
Nov-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Jul-06-21	Initiated	BofA Securities	Neutral
May-20-21	Upgrade	Credit Suisse	Neutral → Outperform
Apr-21-21	Initiated	Truist	Hold
Mar-09-21	Initiated	Credit Suisse	Neutral
Mar-02-21	Upgrade	Citigroup	Neutral → Buy
Feb-17-21	Initiated	Citigroup	Neutral
Feb-12-21	Initiated	Piper Sandler	Neutral
Feb-08-21	Initiated	Tigress Financial	Buy

View All

Hims Hers Health Inc Stock (HIMS) Latest News

Jun 07, 2025

Is Hims & Hers Health a Smart Buy Right Now? - The Motley Fool

Jun 07, 2025

This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space - The Motley Fool

Jun 07, 2025

Jun 06, 2025

Hims & Hers cuts 4% of staff after FDA ban on generic weight-loss drugs - Outsource Accelerator

Jun 06, 2025